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The aim of this study was to identify the risk factors for seizure recurrence after withdrawal of chronic antiepileptic therapy 
in 226 children: 136 with partial epilepsies and 90 with generalized epilepsies. The influence on prognosis of the different 
variables was assessed retrospectively with univariate and multivariate analysis. With a mean observation period of 5.85-t-3.87 
years, seizure recurrence occurred in 24.3% of all patients with partial and generalized epilepsies. In children with partial 
epilepsies, the following factors were found to significantly increase relapse risk after treatment withdrawal: neurological 
abnormalities; interval between seizures less than 1 month at onset of illness; the use of VPA in treating seizures; start of 
withdrawal after 6 years of age; frontal paroxysmal ctivity; and abnormal EEG before drug withdrawal. In children with 
generalized epilepsies the risk factors were found to be: abnormal neonatal period; first seizure after 10 years of age; mean 
duration of seizures greater than 1 minute; poor school progress and generalized spike-waves in EEG. The factors associated 
with the risk of recurrence in children with generalized epilepsy appear to differ from to those related to partial epilepsies, 
in which seizure treatment with VPA was associated with an increased recurrence risk after the withdrawal of antiepileptic 
drugs. 
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INTRODUCTION 
Epilepsy is a chronic disease that can be controlled 
in 70-80% of cases with appropiate medication 1-4. 
Actually, when a patient has been seizure-free for at 
least 2 or 3 years, withdrawal of long-term therapy 
should be considered in order to reduce the poten- 
tial risk of pharmacological side-effects and to avoid 
the psychosocial problems which may affect qual- 
ity of life. Besides, the discontinuation of antiepilep- 
tic drugs (AEDs) considerably reduces the economic 
cost of medication and hematological and clinical 
assessments 5, 6. 
Prognostic studies after withdrawal of AED in pa- 
tients with epilepsy report widely differing percent- 
ages of seizure recurrence (6-60%) and there is lit- 
tle agreement as to the factors involved 7-2°. In gen- 
eral, these studies analyse heterogeneous groups of 
patients with different ypes of epilepsy and, with few 
exceptions, fail to evaluate the influence on recur- 
rence of previously administered AED 7' 10, 12,14.21 
The aim of this study is to evaluate the prognosis 
for children with epilepsy after withdrawal of long- 
term treatment. Two homogeneous groups of patients 
with partial or generalized epilepsies were studied 
evaluating, in both groups, the relapse rate and the 
factors influencing outcome, including the AED in- 
volved. 
MATERIALS AND METHODS 
The hospital records of 240 children who were un- 
der 15 years of age at the start of treatment with- 
drawal have been reviewed. These children had been 
diagnosed as epileptic (with two or more epilep- 
tic seizures, and with ictal and/or interictal paroxys- 
mal EEG abnormalities) and evaluated as outpatients 
between 1977 and 1994 at the University Hospital 
'Marqu6s de Valdecilla' in the Neuropediatry Depar- 
ment. This is a reference centre for the 500,000 res- 
idents of Cantabria, a region in the north of Spain. 
Chronic treatment had been discontinued with all the 
240 study participants after they had been seizure-free 
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for at least 2 years. Children with a single epileptic 
seizure and/or febrile seizures were excluded. 
The following variables were evaluated in each pa- 
tient: (1) sex; (2) epilepsy and/or febrile seizures in 
first-grade relatives; (3) pregnancy, birth and neona- 
tal period; (4) psychomotor development, ype of 
school, neurological examination at onset of seizures 
and during the follow-up period; (5) age at the time 
of first seizure; (6) seizure characteristics: number, 
type, duration and time of occurrence; (7) epilep- 
tic syndrome; (8) EEG findings; (9) CT scan; (10) 
AED therapy--AEDs administered, number of AEDs 
tried, mono or polytherapy, serum levels attained, 
'lost time' between onset of seizures and the start 
of treatment and length of treatment; (11) character- 
istics of withdrawal--time that the patient has been 
seizure-free before withdrawal, age at the moment of 
withdrawal, duration of withdrawal period; (12) data 
related to seizure recurrence--number, type and du- 
ration of seizure and response to reintroduction of 
AED. 
Forty of the children had suffered some type of 
pathology during the neonatal period: five, meningi- 
tis; six, brain hemorrhage; four, severe hypoxia; eight, 
seizures (all of them due to temporary metabolic dis- 
turbances, no longer than 48 hours in any of the 
cases); six, jaundice; five, vomiting; four, premature 
labor, and two, intrauterine delayed growth. The small 
number of patients in each subgroup makes the statis- 
tical analysis difficult, thus all patients that had any 
type of neonatal pathology were gathered together. 
As a result the 226 patients in the study were di- 
vided into two groups: 186 children who had had no 
problems during the neonatal period; and 40 with an 
abnormal neonatal period. 
All children underwent EEG at the onset of ill- 
ness, annually and before drug withdrawal. In all 
cases photostimulation a d hyperventilation i  col- 
laborative patients was included. Spontaneous sleep 
EEG, were recorded in all children under 6 years of 
age, and polysomnography or 24-hour EEG moni- 
toring was carried out where necessary for a con- 
clusive diagnosis. The EEG records were classified 
according to basal activity (normal, focal or globally 
delayed) and the type and placement of the parox- 
ystic activity. Epileptiform abnormalities including 
spike, polyspike, slow spike-wave, spike-wave 3/s, 
polyspike-wave and hipsarritmia. A brain CT scan or 
MR was performed if the child had partial epilepsies 
(except for rolandic epilepsy), symptomatic general- 
ized epilepsies or drug-resistant epilepsies. 
Intellectual capacity was evaluated subjectively in 
all children, and psychometric tests were used in 41 
cases. Children with an IQ > 85 were considered 
normal, IQ 71-84 borderline, IQ 50-70 mild mental 
retardation, IQ 35-49 moderate mental retardation, IQ
less than 35 severe mental retardation. 
AEDs were administered in monotherapy wherever 
possible, with doses attaining serum levels within 
the following therapeutic ranges: 4-8 /zg/ml carba- 
mazepine (CBZ), 50-100 /.tg/ml valproate (VPA), 
20-30 #g/ml phenobarbitone (PB) or PB derived 
from primidone (PRM), and 10-20/zg/ml phenytoin 
(PHT). Withdrawal of treatment was carried out in 
general over 12 months: one-sixth of the total drug 
dose was withdrawn in the first 3 months, one-fifth 
in the second 3 months, and the rest in the remaining 
6 months. The serum levels of the AED were mon- 
itored from the beginning of treatment until seizure 
control was achieved. Analyses were repeated twice 
a year during treatment. 
Data collection on the 240 patients ended on 31 Oc- 
tober 1996, and all epileptic seizures occurring dur- 
ing the period of drug withdrawal and/or after total 
drug suppression were considered as recurrences. In- 
formation on the progress of the children was ob- 
tained through personal contact, when they attended 
the hospital for neurological testing, and/or thereafter 
by telephone. In order to contrast his information 
and evaluate the progress of those patients who could 
not be contacted, we reviewed the clinical records 
of the three hospitals with adult neurology units in 
Cantabria. This enabled us to check whether they 
had been hospitalized or were again receiving AED. 
Finally, we verified the records of the lone Clinical 
Pharmacology Service in the region to check whether 
the serum levels of AEDs had been measured in any 
of the patients. During the follow-up period, 14 out of 
240 children were withdrawn from the study since we 
were unable to check whether they had had seizures 
after the chronic treatment was permanently stopped, 
nine were found to have had partial epilepsies (six 
temporal, two rolandic, one frontal epilepsies) and 
five had had generalized epilepsies (three tipical ab- 
sences and two grand mal). Thus, the final analysis 
was done with 226 children, applying the diagnostic 
criteria established by the Commision for Terminol- 
ogy and Classification of the ILAE in 1989 (Table 1): 
136 children with partial epilepsies and syndromes 
and 90 with generalized ones. 
The data were introduced into a data-base created 
with EPI-INFO 6.0, carrying out univariate analysis 
of dichotomic variables with the chi-square test anal- 
ysis of variance of continuous variables. The multi- 
variate analysis was performed with the Biomedical 
Package Dynamic statistical program version 1993 
(BMDPDYN). The probability of recording a recur- 
rence depends on the time of follow-up so the Cox 
proportional hazards model was used for the mul- 
tivariate analysis. Since the type of epilepsy (par- 
tial/generalized) is a determinant risk factor, all 226 
children in the study were analysed and separated into 
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Table 1 : Classification of epilepsies and epileptic syndromes 
Sydrome Number (Percentage) 
Localization-related (focal, partial) epilepsies and syndromes 
Idiopathic 
Benign childhood epilepsy with centrotemporal spikes 
Criptogenic/symptomatic 
Epilepsy with locus at onset unknow 
Epilepsy from frontal Iobe'hhT 
Epilepsy from parietal lobe 
Epilepsy from temporal lobe 
Epilepsy from occipital lobe 
Generalized epilepsies and syndromes 
Idiopathic 
Benign myoclonic epilepsy in infancy 
Childhood absence epilepsy 
Epilepsy with grand-mal seizures (GTCS) 
Other generalized i iopathic epilepsies 
Criptogenic/symptomatic 
West syndrome" 
Lennox-Gastaut syndrome" hhT 
Epilepsy with myoclonic-astatic seizures 
Epilepsy with myoclonic absences 
136 (60.2%) 
36(15.9%) 
36(15.9%) 
100(44.2%) 
5 (2.2%) 
6 (2.7%) 
12 (5.4%) 
66 (29.2%) 
11 (4.9%) 
90 (39.8%) 
54(23.9%) 
1 (0.4%) 
21 (9.3%) 
28 (12.3%) 
4 (1.8%) 
36(15.9%) 
17 (7.5%) 
6 (2.6%) 
3 (1.3%) 
8 (3.5%) 
two groups: 136 with partial epilepies and syndromes 
and 90 with generalized ones. Once the three mod- 
els of independent predictive factors for each group 
of patients was obtained in the multivariate analysis, 
it was proved that the seizure recurrence in children 
with partial epilepies was influenced by the adminis- 
tered drug. All the drugs were included in this model 
in order to determine whether a significant difference 
could be observed with the risk of recurrence. 
RESULTS 
Patient characterist ics 
The study involved 226 children: 136 (60.2%) with 
partial epilepsies; and 90 (39.8%) with generalized 
epilepsies. Of these 116 (51.3%) were males, and al- 
most a quarter (22.5%) had a history of epilepsy in 
first-grade relatives; pregnancies and births were ab- 
normal in 10% of cases; and 29 children (12.8%) had 
previously suffered febrile seizures. Neuropsycholog- 
ical evaluation was normal in 85% of cases both at 
the start of treatment and during the course of the ill- 
ness, so epilepsy did not appear to have had a nega- 
tive effect on cognitive functions. Twenty-eight chil- 
dren (12.4%) required psychopedagogical help, and 
34 (15%) special schooling, the latter children be- 
ing specifically those with mental retardation. Slow 
educational progress was more frequent in children 
with cryptogenic or symptomatic generalized epilep- 
sies (13 out of 24 children, 54%). Other clinical fea- 
tures are shown in Table 2. 
Table 2: Clinical characteristics of cohort 
No. of children (males) 
Mean age of onset (months) 
Etiology 
Idiopathic 
Criptogenic 89 (39.4%) 
Symptomatic 47(20.8%) 
Monothefapy 
'Lost time' (months) 
Mean age of active pilepsy (months) 
Mean duration of seizure free (months) 
Mean age at onset of treatment (months) 
Mean duration of treatment (months) 
Mean duration of withdrawal (months) 
226 (116) 
53.25 4- 35.35 
90 (39.8%) 
191 (84.5%) 
4.96 4- 9.44 
16.44 - 20.65 
38.87 -4- 16.77 
57.97 4- 35.75 
50.50 4- 27.47 
11.97 4- 3.69 
The drugs used for seizure treatment were as fol- 
lows: PB in 48 children, PRM in 32, PHT in 14, 
CBZ in 55 and VPA in 77. The doses administered at- 
tained serum levels in the medium to high therapeutic 
ranges. Children with generalized epilepsies received, 
in general, VPA (56.7%), especially those with ab- 
sences, myoclonus or infantile spasms, whilst other 
drugs were rarely prescribed (CBZ in three cases, 
PHT in five, PB in 14 and PRM in 17). In the children 
with partial epilepsies the drug distribution was more 
homogeneous (Table 3), although CBZ was preferred 
in patients with rolandic epilepsy. In 84.5% of the 
children, complete control of seizures was achieved 
with monotherapy and it is noteworthy that in 65.9% 
of the children seizures were suppressed by the first 
drug administered. No differences relating to the fre- 
quency of seizures (p = 0.43) were shown among 
the type of drug administered in the group of chil- 
dren with partial epilepsies, neither with the number 
of drugs needed to control them (p = 0.101), nor 
with the administration regimen in mono or polyther- 
apy (p = 0.093). 
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Table 3: Drug used in relation to location of paroxystic activity 
in children with focal epilepsy 
Rolandic Frontal Parietal Temporal Occipital 
PB 6 2 3 19 3 
PRM - -  1 2 9 2 
PHT 1 - -  2 5 1 
CBZ 20 3 2 23 2 
VPA 9 - -  3 10 3 
Table 4: Risk factors after AED withdrawal in 226 patients. 
Multivariate analysis 
Factor R R 95 % C I 
Type of epilepsy (Focal vs Generalised) 3.09 1.72-5.54 
Abnormal neurological examination 2.59 1.22-5.51 
Location of paroxystic activity 
Frontal 3.89 1.23-12.29 
Parietal 2.86 1.23-6.69 
Seizure type 
Simple partial 1.89 0.96-3.71 
Absences/spasms 0.37 0.14-0.92 
Drug administered (VPA) 3.48 1.87-6.46 
Poor school progress 1.28 1.06-1.53 
Age > 5 years at onset of withdrawal 1.25 1.12-1.39 
Table 5: Risk factors of seizure relapse after aed withdrawal 
in 136 children with focal epilepsies: multivariate analysis. 
Factor RR 95% CI 
Abnormal neurological exploration 3.67 1.61-8.36 
Interval between seizures < I month 
at onset of disease 3.33 1.25-8.82 
Drug administered 
CBZ 0.46 0.17-1.22 
VPA 3.31 1.41-7.72 
Age at onset of withdrawal >6 years 1.22 1.07-1.39 
Frontal paroxystic activity 6.50 1.89-22.29 
Abnormal EEG prior to withdrawal 2.21 0.96-5.06 
Most EEGs were carried out during spontaneous 
sleep following privation (59.2%), 25.2% of children 
were studied exclusively while awake, polygraphic 
EEGs were done in 14.6% of cases and 24-hour EEG 
monitoring in 0.9%. Paroxystic activity was recorded 
in all the children. Basal activity was slow in 40 chil- 
dren (17.7%), 17 with infantile spasms. The frontal 
paroxystic activity, in the univariate analysis, signif- 
icantly increased the risk of recurrence (p = 0.024), 
this can be confirmed in the multivariate analysis (see 
Tables 4 and 5) 
ASSESSMENT OF RECURRENCE RISK 
The mean period of observation was 5.85+3.87 years, 
with a minimum of 2 years in 201 children (88.83%), 
over 5 years in 122 (53.98%) and more than 10 years 
in 42 children (18.58%). 
At the end of the observation period, 55 of the 226 
children studied (24.3%) had suffered recurrence of 
epileptic seizures after treatment withdrawal, 41 of 
the 136 children with partial epilepsies (recurrence 
index 30.1%), and 14 of the 90 children with gen- 
eralized epilepsies (recurrence index 15.6%). These 
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relapses occurred during dose reduction of drugs in 
17 children (30.9% of all recurrences) and after com- 
plete suspension of treatment in 38 (69.1% of recur- 
rences). Therefore, although many relapses occurred 
during treatment withdrawal, the probability of re- 
maining seizure-free decreased constantly over the 
observation period, and 7 (12.7%) late relapses were 
observed 5 years after terminating drug withdrawal. 
Previously administered treatment was restored to 
51 of the 55 children who relapsed and only 7 of 
these showed therapeutic resistance. 
Global assessment of risk factors for relapse in multi- 
variate analysis (Table 4) When long-term treatment 
is suspended, children with partial epilepsies how a 
relapse risk three times greater than that of children 
with generalized epilepsies (RR 3.09, 95% CI: 1.72- 
5.54). 
The greatest risk of recurrence is observed in chil- 
dren with simple partial seizures, whilst risk was very 
low in children with absences or infantile spasms. 
Comparing relapse rates in children with AED with- 
drawal before 3 years of age, between 3-5 years of 
age, between 5-10 years and after 10 years of age, 
the greatest risk of recurrence was seen when treat- 
ment was suspended after 5 years of age. In the same 
way, children with poor school progress and/or neu- 
rological abnormalities had a significantly higher risk 
of recurrence. 
Regarding the assessment of the AED adminis- 
tered, relapse risk was found to be significatly greater 
in children treated with VPA, and the following se- 
quence can be established, from greater to smaller isk 
of recurrence: VPA >> PHT > PB > PRM > CBZ. 
Risk factors in children with partial epilepsies and syn- 
dromes in multivariate analysis (Table 5) Relapse risk 
was three times greater in children whose initial 
seizures occurred in less than 1 month, as compared 
with children who had seizures over a more extended 
period (RR 3.33, 95% CI: 1.25-8.82). The risk was 
also greater in children with partial epilepsies who 
showed neurological disorders prior to the onset of 
seizures, with paroxysmal EEG in the frontal lobe 
or when suppression of treatment was started after 6 
years of age. 
Regarding the administered AEDs, children with 
partial epilepsies treated with VPA showed a three 
times greater isk of recurrence (RR 3.31, 95% CI: 
1.41-7.72). Comparing children treated with differ- 
ent AEDs (Table 6), it can be seen that those treated 
with VPA showed a greater isk of recurrence than 
those treated with any other drug: 2.67 times that 
of PB (95% CI: 1.07-5.08); 4.28 times that of PRM 
(95% CI 1.3-14.01); 3.38 times that of PHT (95% CI: 
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Table 6: Risk of seizure relapse comparing patients with 
partial epilepsies treated with different drugs. 
PB PRM PHT CBZ VPA 
PB 1.60 1.26 2.66 0.36 
PRM 0.62 0.74 1.67 0.23 
PHT 0.79 1.26 2. I 1 0.29 
CBZ 0.37 0.59 0.47 0.13 
VPA 2.67 4.28 3.38 7.15 
Bold figures are significant. 
Table 7: Risk factors of seizure relapse after aed withdrawal in 
90 children with generalised epilepsies, multivariate analysis. 
Factor RR 95% CI 
Pathological neonatal period 1.34 
Age > 10 years at first seizure 1.03 
Mean duration of seizures < I minute 0.19 
Poor school progress 2.01 
Generalised groups of irregular 
spike-wave in EEG 19.42 
1.09-1.65 
1.01-1.06 
0.03-0.96 
1.22-3.31 
3.63-103.67 
0.99-11.59); and 7.15 times that of CBZ (95% CI: 
2.45-20.83). For this group of patients, the follow- 
ing sequence can be established as regards adminis- 
tered drug, from greater to smaller isk of recurrence: 
VPA >> PB > PHT > PRM >> CBZ. 
Risk factors in children with generalized epilepsies and 
syndromes in multivariate analysis (Table 7) In chil- 
dren with generalized epilepsies, an abnormal neona- 
tal period increased the risk of recurrence after treat- 
ment withdrawal (RR 1.34, 95% CI: 1.09-1.65), as 
did seizures with a duration of more than 1 minute, 
poor school achievement and generalized irregular 
spike-wave in EEG. When children with generalized 
epilepsies were over 10 years of age at the onset of 
seizures, the recurrence index was markedly increased 
(RR 1.03, 95% CI: 1.01-1.06). 
DISCUSSION 
Following the withdrawal of long-term treatment, 
24.3% of patients relapsed, a similar propor- 
tion to that reported in other studies, both for 
children 7, I 0, 15, 18-20, 22-24, and for adults 2I, 25, 26. 
Most studies suggest hat the type of epilepsy or 
epileptic syndrome is a prognostic factor for treat- 
ment withdrawal8-10, 13, 14, 16-18,20,22,23,25,27-29 but
few authors have analysed relapse-risk factors in ho- 
mogeneous populations of epileptics: Ehrhardt and 
Forsythe 15, studied children with generalized tonic- 
clonic seizures; Tsai and Schmidtl2; children with 
complex partial seizures; and Shinnar et a/.2°; chil- 
dren with idiopathic epilepsies and with crypto- 
genic/symptomatic epilepsies. It is clear that a cor- 
rect analysis of relapse risk requires elected groups 
of patients. When children with different forms of 
epilepsy are compared, we find that the factors influ- 
encing seizure relapse after treatment withdrawal vary 
according to type of epilepsy or epileptic syndrome, 
and that children with partial epilepsies present a re- 
lapse risk three times greater than that of children 
with generalized epilepsies. In the study carried out 
by Donati et al. 24, on children with partial epilepsies, 
a relapse rate of 29.3% is reported which is similar 
to the 30% observed in our patients with this type of 
epilepsy. 
Most authors indicate that 60-85% of re- 
lapses occur early, during withdrawal of 
treatment 7-1°'12,15"23'28 In our study, only 17 of 
55 children (30.9%) had early recurrences. In 20 
cases (40%), relapse occurred after 1 year without 
treatment, and in 7 children (12.7%) even after more 
than 5 years without treatment. This difference may 
be explained by the method followed for suppres- 
sion of treatment, which has usually been carried out 
without considering the characteristics of the AEDs 
involved (rapid suppression of barbiturates, alter- 
ations in serum levels on suspending one or more 
drugs used in polytherapy) and this, in itself, could 
justify seizure recurrence 3°-32. In fact, in studies 
where treatment withdrawal is s lower  14'16'19'27'33 
the index of early relapses is lower, around 50%. 
Tennison et al. 34, compared two randomized groups 
in which treatment was suspended over 6 weeks or 
over 9 months, observing that, although in the group 
with faster withdrawal relapses occurred earlier, the 
total relapse index was the same for both groups 2 
years after the withdrawal. In our study, patients with 
a 12-month withdrawal schedule taking into account 
the pharmacokinetic and pharmacodynamic charac- 
teristics of the AEDs involved, early relapse was less 
frequent, but in the long run the total relapse rate 
was similar to these observed in studies with other 
withdrawal policies. For the Medical Research Coun- 
cil Antiepileptic Drug Withdrawal Study Group 35 
there was no evidence that the decision to discon- 
tinue AEDs influenced the long-term prognosis of 
epilepsy. Thus, we consider that the total frequency 
of recurrences i independent of the policy of AED 
withdrawal, although relapses will occur sooner in 
patients ubjected to a rapid withdrawal which fails 
to consider the pharmacokinetic characteristics of the 
drugs involved. 
We have found that in children with generalized 
epilepsies, relapse risk is greater in those with neona- 
tal problems, possibly because arly cerebral alter- 
ations may cause permanent and diffuse lesions with 
a potential for causing generalized paroxysmal ac- 
tivity. No study has analysed the influence of the 
neonatal period, strictly speaking, on seizure relapse 
after withdrawal of long-term treatment. However, 
if we consider that neonatal pathology frequently 
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determines the symptomatic etiology of epilepsies, 
when analysing etiology most authors consider that 
children with symptomatic epilepsies have a poorer 
outlook 9,10,12, 13,20.23,25.27,36,37 
Only a few studies have related relapse index to 
the characteristics of seizures such as duration and 
frequency at onset of illness. For Todt 9, the outlook 
is significantly poorer when seizures last more than 
15 minutes. However, in our study we found that for 
children with generalized epilepsies, outcome after 
treatment withdrawal was poorer when seizures lasted 
more than 1 minute, probably due to the fact that 
children with absences and with infantile spasms pre- 
sented the lowest relapse rate in this group of patients. 
Ehrhardt and Forsythe 15 are the only authors to study 
the influence of the time interval in which seizures oc- 
curred at the onset of illness, but they only evaluated 
patients with generalized tonic- clonic seizures, with- 
out establishing any significant relationship between 
this factor and the relapse index. We have observed 
that, in children with partial epilepsies whose initial 
seizures occurred grouped together over less than a 
month, the outcome after treatment withdrawal was 
significantly poorer. 
Age at onset of seizures is a predictive factor 
considered by many authors, although there is lack 
of agreement as to the age involved in higher re- 
lapse risk. For Emerson et al. 7, and Ehrhardt and 
Forsythe 15, outlook after treatment withdrawal is poor 
when seizures begin at an early age, before 2-3 years 
of age. According to Shinnar et al. 1°, the outlook is 
significantly better when seizures commence before 
the age of 2, while other authors find that relapse 
risk is greater when onset of seizures occurs dur- 
ing adolescence 7, 37, 38. When epileptic seizures occur 
very precociously, these are usually secondary to se- 
rious perinatal pathology and, consequently, in those 
studies which include a large number of patients with 
symptomatic etiology, early onset will worsen the 
outlook, whereas when the majority of patients have 
idiopathic epilepsies, age at the onset of seizures will 
not influence outlook after treatment withdrawal 7. In 
our study, on the other hand, of children with general- 
ized epilepsies, neonatal abnormalities are not related 
to age at the onset of seizures, since the children with 
poorer outcomes were those with onset of seizures af- 
ter age 10. 
There is no agreement as regards the value of EEG 
as a predictive factor for outlook after treatment with- 
drawal. These differing results may be due to dif- 
ferences at the moment in which the EEG is car- 
ded out, and in methodology and interpretation of 
EEG traces 39. Indeed, EEG monitoring which is ex- 
cessively brief and/or carried out with inappropiate 
techniques may result in more difficult detection of 
epileptiform activity, whereas this may become more 
evident in more prolonged monitoring or when ad- 
equate methodology is used (polysomnography, 24- 
EEG hour monitoring, etc.). According to Tinuper 
eta / .  40'41 , and Galimberti et al. 42, an EEG before 
the start of AED withdrawal has no predictive value, 
whereas, if paroxysmal activity increases after start- 
ing withdrawal, relapses will also increase signifi- 
cantly. However, for Todt 9.43 the presence of parox- 
ysmal alterations during the active phase of illness 
has an important influence on outlook. Our study 
shows that, in children with partial epilepsies, EEGs 
performed before the termination of the chronic treat- 
ment have a better prognostic interest han those per- 
formed during the course of the disease. According to 
Andersson et al. 44, children with generalized epilep- 
sies who had irregular spike-wave activity in the 
recordings made before AED withdrawal had a higher 
relapse rate. Studies by Emerson et al. 7, Okuma and 
Kumashiro 45, and Pestre et al. 28 are the only ones that 
describe the patient disease prognostic after stopping 
the treatment, with paroxistic occipital foci or ante- 
rior temporal associated with a good prognosis. Our 
study is the only one that evaluates the frontal parox- 
ystic activity of the EEG with increasing recurrences 
once treatment has been stopped. 
The influence of the previously administered AED 
has only rarely been considered. Overweg et a/. 21, 
observed a higher relapse index in patients where the 
suspended rug was PB or PRM, but they did not 
describe the withdrawal schedule, an aspect which 
is especially important with barbiturates. Tsai and 
Schmidt 12, conclude that the AED involved has no in- 
fluence on the outlook after withdrawal, they also fail 
to indicate the methodology used in their study. In the 
only randomized study using standardized therapeutic 
schedules 14, patients treated with VPA relapsed more 
frequently than those treated with PHT, and even 
more than those treated with CBZ. In our study, chil- 
dren with partial epilepsies treated with VPA showed 
a relapse risk 2.67 times greater than those treated 
with PB, 4.28 times greater than those treated with 
PRM, 3.38 times greater than those treated with PHT, 
and 7.15 times greater than those treated with CBZ. 
Since our study is a retrospective one, it is possible 
that the children treated with VPA belong to a sub- 
group without response to treatment (children with 
partial symptomatic epilepsies, with Lennox-Gastaut 
Syndrome, etc.). However, in children with partial 
epilepsies the choice of drugs was not biased, with- 
out differences among the children treated with VPA 
and the ones treated with other drugs in relationship 
with the number of seizures, number of drugs used 
to control them and whether those used were ad- 
ministered in mono- or polytherapy. In children with 
rolandic epilepsies CBZ was preferred. Although this 
may affect the favourable influence of CBZ on the 
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outcome, it is significant to note that of the 36 chil- 
dren with rolandic epilepsy, the five who relapsed had 
been treated with VPA and there were no significant 
differences in the clinical features of the patients with 
this form of epilepsy. Summing up, the children with 
partial epilepsies treated with VPA do not represent 
an especially resistant subgroup and consequently the 
use of VPA was associated with a markedly increased 
risk of recurrence following the withdrawal of the 
AED, and this result should be taken into account 
when selecting, an AED. 
In conclusion, the risk factors of seizure recurrence 
after stopping the chronic treatment appear to be dif- 
ferent among children with partial epilepsies and syn- 
dromes than those with generalized ones. The choice 
of therapy to treat seizures should be based on its ef- 
ficacy to control them, but nevertheless when several 
drugs have a similar efficacy, the incidence of recur- 
rence should be taken in account when treatment is 
stopped. The majority of patients after AED with- 
drawal continue to be asymptomatic and those who 
relapse can generally be controlled by the reintroduc- 
tion of previous treatment. 
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